Having trouble accessing articles? Reset your cache.

With $76M series B, BlackThorn looks to build out neurobehavioral platform

How BlackThorn rebounded from a January clinical setback to raise $76 million to develop its targeted therapies for neurobehavioral disorders

BlackThorn has amassed a $76 million series B round from investors who are banking on the potential of its PathFinder platform to circumvent the issue of patient heterogeneity in neurobehavioral disorders.

New investors Polaris Partners, Premier Partners, Scripps Research

Read the full 399 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE